Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-3: Brelovitug for Chronic Hepatitis Delta Infection
NCT07454837Phase 3Recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of brelovitug in chronic hepatitis D (2 arms), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Proportion of participants with undetectable HDV RNA (<LLOQ Target not detected [TND]) at 24 weeks. Started Feb 2026; status: recruiting.
02
Drugs
brelovitug
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT07454837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454837.